Medicines policy may be halting Government’s drive for growth
Lilly is calling for Government to freeze the statutory scheme repayment rate for 2023
Read More
Tag: Lilly
Lilly, Incyte’s Olumiant fails in COVID-19 trial
The drug failed to significantly reduce progression to ventilation or death in patients hospitalised with COVID-19
Read More
Lilly enrols first patient in new COVID-19 trial
The study will advance understanding of baricitinib’s potential as a treatment for the virus
Read More
Lilly signs up for access to Evox’ tech in R&D deal
Evox’ technology modifies exosomes to deliver drugs to areas currently inaccessible
Read More
Lilly bags expanded EU approval for Taltz
Taltz has been granted an additional indication for the treatment of patients across the full axSpA spectrum
Read More
Lilly’s Retevmo wins US nod for specific lung, thyroid cancers
The selective RET kinase inhibitor was cleared under the regulator’s accelerated approval process
Read More
Lilly to test Olumiant, LY3127804 against COVID-19
The RA drug Olumiant will be assessed in patients hospitalised with the virus
Read More
Lilly launches first of its kind trial for RET fusion-positive NSCLC
Selpercatinib was designed to inhibit native RET signaling as well as anticipated acquired resistance mechanisms
Read More
Lilly’s Cyramza hits first-line NSCLC trial targets
Lilly is gearing up to file Cyramza for first-line treatment of certain lung cancer patients, after new trial data showed that the drug significantly extended progression-free survival (PFS) in this setting.
Read More
European Commission approves Lilly’s Emgality for migraine
Eli Lilly has confirmed that Emgality, a once-monthly monoclonal antibody injection, has been approved by the European Commission for preventive treatment of migraine in adults who have at least four migraine days per month.
Read More
Lilly files lasmiditan for migraine
Eli Lilly has filed an application in the US to market lasmiditan for the acute treatment of migraine with or without aura in adults.
Read More
Lilly says Trulicity cut risk of CV events in wide patient group
Lilly says its once-weekly diabetes drug Trulicity cut major adverse cardiovascular events (MACE) in patients taking part in the REWIND trial.
Read More
- King’s Doctoral Training Centre to investigate MS symptom management
- Agenda announced for FlyPharma Vienna 2024
- Therapy reprogrammes immune cells to shrink prostate and bladder cancers
- Researchers combine herpes virus with cancer vaccine to treat brain cancer in children
- UK MRC and AstraZeneca partner for translational clinical research
